TR201110525A2 - Water-soluble pharmaceutical compositions for use in the treatment of bone diseases. - Google Patents

Water-soluble pharmaceutical compositions for use in the treatment of bone diseases.

Info

Publication number
TR201110525A2
TR201110525A2 TR2011/10525A TR201110525A TR201110525A2 TR 201110525 A2 TR201110525 A2 TR 201110525A2 TR 2011/10525 A TR2011/10525 A TR 2011/10525A TR 201110525 A TR201110525 A TR 201110525A TR 201110525 A2 TR201110525 A2 TR 201110525A2
Authority
TR
Turkey
Prior art keywords
treatment
water
pharmaceutical compositions
bone diseases
soluble pharmaceutical
Prior art date
Application number
TR2011/10525A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2011/00151A external-priority patent/TR201100151A2/en
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/10525A priority Critical patent/TR201110525A2/en
Priority to PCT/TR2012/000007 priority patent/WO2012093976A1/en
Publication of TR201110525A2 publication Critical patent/TR201110525A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş hiperkalsemi, osteoporoz, tümör osteolizi, malin hiperkalsemi, metastatik kemik hastalığı, periprostatik kemik kaybı, Paget hastalığı gibi kemik hastalıklarının tedavisinde ve/ veya önlenmesinde kullanılmak üzere suda çözünebilir formülasyonlar ve bunların üretim yöntemleri ile ilgilidir.The present invention relates to water-soluble formulations and methods of their production for use in the treatment and / or prevention of bone diseases such as hypercalcemia, osteoporosis, tumor osteolysis, malignant hypercalcemia, metastatic bone disease, periprostatic bone loss, Paget's disease.

TR2011/10525A 2011-01-06 2011-10-24 Water-soluble pharmaceutical compositions for use in the treatment of bone diseases. TR201110525A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2011/10525A TR201110525A2 (en) 2011-01-06 2011-10-24 Water-soluble pharmaceutical compositions for use in the treatment of bone diseases.
PCT/TR2012/000007 WO2012093976A1 (en) 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (en) 2011-01-06 2011-01-06 Ibandronate formulation.
TR2011/10525A TR201110525A2 (en) 2011-01-06 2011-10-24 Water-soluble pharmaceutical compositions for use in the treatment of bone diseases.

Publications (1)

Publication Number Publication Date
TR201110525A2 true TR201110525A2 (en) 2012-07-23

Family

ID=45722687

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/10525A TR201110525A2 (en) 2011-01-06 2011-10-24 Water-soluble pharmaceutical compositions for use in the treatment of bone diseases.

Country Status (2)

Country Link
TR (1) TR201110525A2 (en)
WO (1) WO2012093976A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540488A1 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
WO2010117346A2 (en) * 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility

Also Published As

Publication number Publication date
WO2012093976A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
WO2013009701A3 (en) Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
MX2021006531A (en) Rna containing composition for treatment of tumor diseases.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MD4733B1 (en) Anti-TIGIT antibodies
MX2012013731A (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules.
MX2016002544A (en) Compounds useful as immunomodulators.
IN2012DN02736A (en)
GB201209613D0 (en) New compounds
MX2015006152A (en) Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants.
MX343688B (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same.
MX2013010343A (en) Compositions and methods for transplantation of colon microbiota.
EP2576578A4 (en) Polymorphs of 2'-o-fucosyllactose and producing thereof
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX352324B (en) Multivalent synthetic nanocarrier vaccines.
MX341395B (en) Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
MX370721B (en) Novel compounds and compositions for targeting cancer stem cells.
MX348823B (en) Stable formulations of linaclotide.
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
MY196771A (en) Vesicles which include epidermal growth factor and compositions that contain same
MX342119B (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
MX2019012375A (en) Lfa-1 inhibitor formulations.
CY1116158T1 (en) Substituted 2-oxo- and 2-thiooxy-dihydroquinoline-3-carboxamides as KCNQ2 / 3 modulators
EP2528440A4 (en) Substituted norindenoisoquinolines, syntheses thereof, and methods of use